NCT01843205View on ClinicalTrials.gov

Buspirone as a Candidate Medication for Methamphetamine Abuse

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Methamphetamine DependenceMethamphetamine Abuse
Interventions
DRUG

Methamphetamine

The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.

DRUG

Placebo

The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.

Trial Locations (1)

40536

University of Kentucky Medical Center, Lexington

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of Kentucky

OTHER

NCT01843205 - Buspirone as a Candidate Medication for Methamphetamine Abuse | Biotech Hunter | Biotech Hunter